J&J Defends Invokana Safety Track Record, Amid FDA’s SGLT2 Review
Executive Summary
J&J’s push to expand the successful drug to earlier use and more labeled indications is under a shadow due to the risk for diabetic ketoacidosis, but it said the condition is very rare and endocrinologists caution against reading too much into case reports flagged by FDA.